• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Scilex Holding Company Announces that its Majority Stockholder, Sorrento Therapeutics, Inc., has Issued a Supplement to its Previously Issued "FAQ" Regarding the Dividend of Scilex Holding Company Common Stock

    2/2/23 1:15:35 PM ET
    $SCLX
    $SRNE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $SCLX alert in real time by email

    PALO ALTO, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX) announced that its majority stockholder, Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))) today posted a supplement to its previously issued "Frequently Asked Questions" document under the "Investors" section of its website at www.sorrentotherapeutics.com regarding its recent dividend to Sorrento stockholders of shares of common stock of Scilex Holding Company held by Sorrento.

    The supplement to the FAQs provides notice regarding the Depository Trust and Clearing Corporation's removal of the contra-CUSIP on Scilex common stock that was distributed as a dividend to Sorrento's stockholders and provides notice to brokerage firms, banks, dealers and similar organizations listed therein that a dividend confirmation had previously been distributed to such firms by Scilex's transfer agent and requests that such firms contact Scilex's transfer agent if they have not received such confirmation. The supplement also reiterates a question related to issues that may arise with respect to the dividend in connection with short positions in Sorrento common stock.

    The supplement to the FAQs and related annex are included in this press release and can also be found Scilex's website https://www.scilexholding.com/investors/faqs/

    SUPPLEMENT TO

    FREQUENTLY ASKED QUESTIONS

    REGARDING THE DIVIDEND OF SCILEX HOLDING COMPANY COMMON STOCK BY SORRENTO THERAPEUTICS, INC.

    This supplement is a supplement to the Frequently Asked Questions Regarding the Dividend of Scilex Holding Company Common Stock by Sorrento Therapeutics, Inc. (Sorrento) that was issued by Sorrento on January 29, 2023 (the FAQ), a copy of which can be found under the "Investors" section of its website at www.sorrentotherapeutics.com.

    This supplement is being issued to update and supplement the information in the FAQ to notify investors regarding certain matters relating to the dividend and reiterate certain questions and answers from the FAQ. Capitalized terms used in this supplement shall have their respective meetings set forth in the FAQ.

    NOTICE OF REMOVAL OF CONTRA-CUSIP BY DTCC

    Effective as of February 2, 2023, the Depository Trust and Clearing Corporation has removed the "contra-CUSIP" that it had previously imposed on the Dividend Stock. Any shares of Dividend Stock held by your brokerage firm, bank, dealer or other similar organization for your benefit now bear only Scilex's CUSIP number, which is 80880W106. If you are entitled to receive Dividend Stock, please contact your brokerage firm, bank, or other similar organization immediately to confirm that the CUSIP number appears on your brokerage statement with respect to your Dividend Stock.

    NOTICE TO BROKERAGE FIRMS, BANKS, DEALERS AND OTHER SIMILAR ORGANIZATIONS

    If the name of your firm, bank or other similar organization is set forth on Annex B of the FAQ, which Annex B is repeated below for convenience, and your firm, bank or similar organization has not received the Dividend Confirmation that was mailed to your firm, bank or similar organization, please contact Scilex's transfer agent immediately to obtain a copy of the Dividend Confirmation. Scilex's transfer agent's contact information is as follows:

    Continental Stock Transfer & Trust Company

    Telephone Number: 800-509-5586

    Email Address: [email protected]

    Several major brokers have confirmed to Sorrento and Scilex that they are adding the Scilex share positions to the individual brokerage accounts of Sorrento shareholders receiving the Dividend Stock

    SUPPLEMENTAL QUESTION AND ANSWER

    Q: If I loaned my shares of Sorrento common stock to short sellers or any other party as of the Record Date, am I still entitled to receive Dividend Stock as of the Payment Date? 

    A: Only Record Holders as of the Record Date are entitled to receive the Dividend Stock. If you were the Record Holder as of the Record Date and are entitled to receive the Dividend Stock, but have not received the Dividend Stock, you may be entitled to receive Dividend Stock from the short seller or other party who borrowed your shares of Sorrento common stock, whether through the lending programs implemented by your brokerage firm, bank, dealer and other similar organization or otherwise. If you were a Record Holder as of the Record Date and have not received your Dividend Stock, please consult with your financial advisor, broker or other agent immediately to determine how to receive your Dividend Stock.

    Annex B

    Broker List

    Broker NameBroker Address Broker NameBroker Address
    ABN AMRO CLEARING CHICAGO LLC175 WEST JACKSON BLVD.

    CHICAGO

    IL ILLINOIS

    60604 US
     Albert Fried & Company LLC45 BROADWAY, 24TH FLOOR

    24TH FLOOR

    NEW YORK

    NY NEW YORK

    10006 US
    AMALGAMATED BANK275 7TH AVENUE

    NEW YORK

    NY NEW YORK

    10003 US
     AMERICAN ENTERPRISE INVESTMENT SERVICES INC.682 AMERIPRISE FINANCIAL CENTER

    MINNEAPOLIS

    MN MINNESOTA

    55474 US
    APEX CLEARING CORPORATION2 GATEWAY CENTER 283-299 MARKET ST

    16TH FLOOR

    NEWARK

    NJ NEW JERSEY

    07102-5005 US
     BANK OF AMERICA, NA/GWIM TRUST OPERATIONS901 MAIN STREET

    12TH FLOOR

    DALLAS

    TX TEXAS

    23113 US
    BANK OF NEW YORK MELLON111 SANDERS CREEK PARKWAY 2ND FLOOR

    2ND FLOOR

    EAST SYRACUSE

    NY NEW YORK

    13057 US.
     BARCLAYS CAPITAL INC.DTC CUSTODY PARTICIPANT- NY WINDOW -570 WASHINGTON BLVD (ATTN: ROSA HICKS-MILLER OR ROBERT MENDEZ

    JERSEY CITY

    NJ NEW JERSEY

    07310 US
    BARCLAYS CAPITAL INC.DTC CUSTODY PARTICIPANT- NY WINDOW -570 WASHINGTON BLVD (ATTN: ROSA HICKS-MILLER OR ROBERT MENDEZ

    JERSEY CITY

    NJ NEW JERSEY

    07310 US
     BMO CAPITAL MARKETS CORP.3 2ND STREET

    12TH FLOOR

    JERSEY CITY

    NJ NEW JERSEY

    07302 US
    BMO HARRIS BANK NA/TRUST11270 W PARK PL

    MILWAUKEE

    WI WISCONSIN

    53224 US
     BMO Nesbitt Burns Inc., Toronto250 YONGE STREET, 7TH FLOOR

    7TH FLOOR

    TORONTO

    ON ONTARIO

    M5B 2M8 CA CANADA
    BNP PARIBAS, NEW YORK BRANCH/BNP PARIBAS PRIME BROKERAGE CUSTODIAN100 WEST 33RD STREET

    3RD FLOOR

    NEW YORK

    NY NEW YORK

    10001
     BNP PARIBAS, NEW YORK BRANCH/BNP PARIBAS PRIME BROKERAGE CUSTODIAN100 WEST 33RD STREET

    3RD FLOOR

    NEW YORK

    NY NEW YORK

    10001
    BNY MELLONPO BOX 392002

    500 ROSS STREET

    PITTSBURGH

    PA PENNSYLVANIA

    15262 US
     BNY MELLON/WEALTH MANAGEMENT1 FREEDOM VALLEY DRIVE

    OAKS

    PA PENNSYLVANIA

    19456 US
    BNYMELLON111 SANDERS CREEK PARKWAY 2ND FLOOR

    2ND FLOOR

    EAST SYRACUSE

    NY NEW YORK

    13057 US
     BNYMELLON/RE BARCLAYS CAPITAL SECURITIES LTD.ONE WALL STREET

    NEW YORK

    NY NEW YORK

    10286
    BNYMELLON/RE CACEIS BANK LUXEMBOURG500 Grant St.

    BNY Mellon Center

    PITTSBURGH

    PA PENNSYLVANIA

    15258
     BNYMELLON/RE CACEIS BANK, NETHERLANDS111 SANDERS CREEK PARKWAY

    EAST SYRACUSE

    NY NEW YORK

    13057
    BNYMELLON/RE CHARLES STANLEY AND COMPANY, LIMITED111 SANDERS CREEK PARKWAY 2ND FLOOR

    2ND FLOOR

    EAST SYRACUSE

    NY NEW YORK

    13057 US
     BNYMELLON/RE ETF - ISHARES DTC/NSCC111 SANDERS CREEK PARKWAY

    EAST SYRACUSE

    NY NEW YORK

    13057
    BNYMELLON/RE WINTERFLOOD SECURITIES LTD500 Grant St.

    BNY Mellon Center

    PITTSBURGH

    PA PENNSYLVANIA

    15258
     BOFA4804 Deer Lake Drive East

    FL9-803-04-04- 4th floor

    JACKSONVILLE

    FL FLORIDA

    32246 US
    BOFA4804 Deer Lake Drive East

    FL9-803-04-04- 4th floor

    JACKSONVILLE

    FL FLORIDA

    32246 US
     BOFA SECURITIES INC4804 Deer Lake Drive East

    FL9-803-04-04- 4th floor

    JACKSONVILLE

    FL FLORIDA

    32246 US
    BROWN BROTHERS HARRIMAN & CO.140 BROADWAY

    ATTN: CORPORATE ACTIONS VAULT

    NEW YORK

    NY NEW YORK

    10005 US
     BROWN BROTHERS HARRIMAN & CO./ETF140 BROADWAY

    NEW YORK

    NY NEW YORK

    10005
    CALDWELL SECURITIES LTD./CDS**55 UNIVERSITY AVENUE

    SUITE 340

    TORONTO

    ON ONTARIO

    M5J 2H7 CANADA
     CANACCORD GENUITY CORP.609 GRANVILLE ST

    VANCOUVER

    BC BRITISH COLUMBIA

    V7Y 1H2 CA CANADA
    CANTOR, FITZGERALD & CO.135 E 57TH ST 5TH FL

    NEW YORK

    NY NEW YORK

    10041 US
     CDS CLEARING AND DEPOSITORY SERVICES INC.100 ADELAIDE STREET WEST

    TORONTO

    ON ONTARIO

    M5H 1S3 CA CANADA
    CETERA INVESTMENT SERVICES LLC400 FIRST STREET SOUTH, SUITE 300

    SUITE 300

    ST. CLOUD

    MN MINNESOTA

    56302-0283 US
     CHARLES SCHWAB & CO., INC.211 MAIN STREET

    SAN FRANCISCO

    CA CALIFORNIA

    94105 US
    CI INVESTMENT SERVICES INC.199 BAY STREET

    SUITE 2600

    TORONTO

    ON ONTARIO

    M5L 1E2 CA CANADA
     CIBC WORLD MARKETS INC./CDS**161 BAY STREET 10 FL

    TORONTO

    ON ONTARIO

    M5J 2S8 CA CANADA
    CITIBANK, N.A./ETF3800 CITIGROUP CENTER

    B2/2

    TAMPA

    FL FLORIDA

    33610
     CITIBANK, NATIONAL ASSOCIATION3800 CITIBANK CENTER TAMPA

    BLDG.B FIRST FLOOR ZONE 8

    TAMPA

    FL FLORIDA

    33610-9122 US
    CITIGROUP GLOBAL MARKETS, INC.580 CROSSPOINT PARKWAY

    GETZVILLE

    NY NEW YORK

    14068 US
     CLEAR STREET LLC4 World Trade Center, 45th Floor

    150 Greenwich Street

    NEW YORK

    NY NEW YORK

    10007
    CLEARSTREET IO55 BROADWAY (SUITE 2102)

    CORPORATE ACTIONS

    NEW YORK

    NEW YORK

    10006 US
     COMMERCE BANK922 WALNUT STREET

    MAIL STOP TBTS-2

    KANSAS CITY

    MO MISSOURI

    64106 US
    COR CLEARING LLC9300 UNDERWOOD AVE

    SUITE 400

    OMAHA

    NE NEBRASKA

    68114 US
     Credential Securities Inc.800-1111 WEST GEORGIA STREET

    VANCOUVER

    BC BRITISH COLUMBIA

    V6E 4T6 CA CANADA
    CREST INTERNATIONAL NOMINEES LIMITED33 CANNON STREET

    LONDON

    EC4M 5SB GB UNITED KINGDO
     CURVATURE SECURITIES, LLC39 MAIN STREET

    CHATHAM

    NJ NEW JERSEY

    07928 US
    D.A. DAVIDSON & CO.8 3RD STREET NORTH

    GREAT FALLS

    MT MONTANA

    59401 US
     DEPOSITO CENTRAL DE VALORES S.A., DEPOSITO DE VALORESAVENIDA APOQUINDO # 4001

    FLOOR 12, C.P.

    7550162, SANTIAGO

    CL CHILE
    DESJARDINS SECURITIES INC.1253 McGill College

    10TH FLOOR

    MONTREAL

    QUEBEC

    H3B 2Y5 CA CANADA
     DEUTSCHE BANK AG NY/US CUSTODY1251 Avenue Of The Americas

    NEW YORK

    NY NEW YORK

    10020
    DEUTSCHE BANK SECURITIES INC.60 WALL STREET

    9TH FLOOR

    NEW YORK

    NY NEW YORK

    10005 US
     DRIVEWEALTH, LLC15 EXCHANGE PLACE

    10TH FLOOR

    JERSEY CITY

    NEW JERSEY

    07302
    E*TRADE CLEARING LLCHARBORSIDE FINANCIAL CENTER

    501 PLAZA 11

    JERSEY CITY

    NJ NEW JERSEY

    07311 US
     EDWARD D. JONES & CO., L.P.12555 MANCHESTER ROAD

    ST. LOUIS

    MO MISSOURI

    63131-3729 US
    EDWARD D. JONES & CO., L.P.201 PROGRESS PARKWAY

    MARYLAND HEIGHTS

    MO MISSOURI

    63043 US
     FIDELITY CLEARING CANADA ULC/CDS**483 BAY ST.

    SOUTH TOWER

    TORONTO

    ON ONTARIO

    M5G2N7 CA CANADA
    FIFTH THIRD BANK5001 KINGSLEY DRIVE

    MAIL DROP 1MOB28

    CINCINNATI

    OH OHIO

    45227 US
     FOLIO INVESTMENTS, INC.8180 GREENSBORO DRIVE

    8TH FLOOR

    MCLEAN

    VA VIRGINIA

    22102 US
    FUTU CLEARING INC.12750 Merit Drive

    SUITE 475

    DALLAS

    TX TEXAS

    75251
     GMP SECURITIES L.P.145 KING STREET WEST, SUITE 300

    11TH FLOOR

    TORONTO

    ON ONTARIO

    MJ5 1J8 CA CANADA
    GOLDMAN, SACHS & CO. LLC222 SOUTH MAIN STREET

    Attn: Mandatory Corporate Actions

    SALT LAKE CITY

    UT UTAH

    84101 US
     HAYWOOD SECURITIES INC./CDS**200 BURRARD ST

    WATERFRONT CENTRE SUITE 700

    VANCOUVER

    BC BRITISH COLUMBIA

    V6C 3L6 CANADA
    HILLTOP SECURITIES INC.1201 ELM ST.

    35TH FLOOR

    DALLAS

    TX TEXAS

    75270 US
     HRT FINANCIAL LLC150 GREENWICH STREET (ATTN: SETTLEMENT) FOUR WORLD TRADE CENTER

    57TH FLOOR

    NEW YORK

    NY NEW YORK

    10007 US
    HSBC BANK USA, NA/HSBC CUSTODY & CLEARING SERVICES FOR STOCK LOAN452 FIFTH AVENUE

    ATTN: HBUS CCS SETTS

    NEW YORK

    NY NEW YORK

    10018 US
     HSBC BANK USA, NATIONAL ASSOCIATION452 FIFTH AVENUE

    ATTN: HBUS CCS SETTS

    NEW YORK

    NEW YORK

    10018 US
    INTERACTIVE BROKERS LLC2 PICKWICK PLAZA

    2ND FLOOR

    GREENWICH

    CT CONNECTICUT

    06830 US
     J.P. MORGAN CHASE BANK NA/FBO BLACKROCK CTF1111 POLARIS PARKWAY

    COLUMBUS

    OH OHIO

    43240
    J.P. MORGAN CLEARING CORP.FOUR CHASE METROTECH CENTER

    3RD FLOOR

    BROOKLYN

    NY NEW YORK

    11201 US
     JANNEY MONTGOMERY SCOTT LLC1717 ARCH STREET

    17TH FLOOR

    PHILADELPHIA

    PA PENNSYLVANIA

    19103 US
    JEFFERIES LLC101 HUDSON STREET, 11th Floor

    NEW JERSEY

    NJ NEW JERSEY

    07302 US
     JPMORGAN CHASE BANK, NATIONAL ASSOCIATIONFOUR CHASE METROTECH CENTER

    3RD FLOOR

    BROOKLYN

    NY NEW YORK

    11201 US
    JPMORGAN CHASE BANK/EUROCLEAR BANKFOUR CHASE METROTECH CENTER

    3RD FLOOR

    BROOKLYN

    NY NEW YORK

    11245 US
     JPMORGAN CHASE BANK/IAFOUR CHASE METROTECH CENTER

    3RD FLOOR

    BROOKLYN

    NY NEW YORK

    11201 US
    KEYBANK NATIONAL ASSOCIATION4900 TIEDEMAN RD

    BROOKLYN

    OH OHIO

    44144 US
     LAURENTIAN BANK SECURITIES INC.1981 MCGILL COLLEGE AVE.

    SUITE 100

    MONTREAL

    QUEBEC

    H3A 3K3 CA CANADA
    LPL FINANCIAL LLC4707 EXECUTIVE DRIVE

    SAN DIEGO

    CA CALIFORNIA

    92121 US
     MANUFACTURERS AND TRADERS TRUST COMPANYONE M&T PLAZA

    TRUST OPS 8TH FLOOR

    BUFFALO

    NY NEW YORK

    14203 US
    MANULIFE SECURITIES INCORPORATED1235 NORTH SERVICE ROAD WEST

    OAKVILLE

    ON ONTARIO

    L6M 2W2 CA CANADA
     MARSCO INVESTMENT CORPORATION101 EISENHOWER PARKWAY

    ROSELAND

    NJ NEW JERSEY

    07068 US
    MERRILL LYNCH, PIERCE, FENNER & SMITH INCORPORATED4804 Deer Lake Drive East

    FL9-803-04-04- 4th floor

    JACKSONVILLE

    FL FLORIDA

    32246 US
     MIRAE ASSET SECURITIES (USA) INC./STOCK LOAN CONDUIT ACCOUNT810 SEVENTH AVE

    37TH FLOOR

    NEW YORK

    NY NEW YORK

    10019
    MIRAE ASSET SECURITIES (USA), INC.810 SEVENTH AVE

    37TH FLOOR

    NEW YORK

    NY NEW YORK

    10019
     MITSUBISHI UFJ TRUST & BANKING CORPORATION, NEW YORK BRANCH280 PARK AVE

    39TH FL-WEST BLDG

    NEW YORK

    NY NEW YORK

    10017
    Morgan Stanley1300 THAMES STREET

    THAMES STREET WHARF

    BALTIMORE

    MD MARYLAND

    21231 US
     MORGAN STANLEY & CO. LLC1300 THAMES ST.

    BALTIMORE

    MD MARYLAND
    MORGAN STANLEY SMITH BARNEY LLC1 NEW YORK PLAZA

    39TH FLOOR

    NEW YORK

    NY NEW YORK

    10004 US
     MURIEL SIEBERT & CO., INC.77 SUMMER STREET

    3RD FLOOR

    BOSTON

    MA MASSACHUSETTS

    02210 US
    NATIONAL FINANCIAL SERVICES LLC499 WASHINGTON BOULEVARD

    5TH FLOOR

    JERSEY CITY

    NJ NEW JERSEY

    07310 US
     NBCN INC.1010 rue De La Gauchetière

    Mezzanine 100

    MONTREAL

    QUEBEC

    H3B 5J2 CA CANADA
    NOMURA INTERNATIONAL TRUST COMPANY309 WEST 49TH STREET

    10TH FLOOR

    NEW YORK

    NY NEW YORK

    10019 US
     ODLUM BROWN LIMITED250 HOWE STREET

    SUITE 1100

    VANCOUVER

    BC BRITISH COLUMBIA

    V6C 3R8 CA CANADA
    OPPENHEIMER & CO. INC.85 BROAD STREET

    NEW YORK

    NY NEW YORK

    10004 US
     PERSHING LLC1 PERSHING PLAZA

    JERSEY CITY

    NJ NEW JERSEY

    07399 US
    PHILLIP CAPITAL INC.141 W. JACKSON BLVD. SUITE 3050

    CHICAGO

    IL ILLINOIS

    60604 US
     PI FINANCIAL CORP.666 BURRARD ST

    SUITE 1900

    VANCOUVER

    BC BRITISH COLUMBIA

    V6C 3N1 CA CANADA
    PNC BANK, NATIONAL ASSOCIATION4100 W 150TH STREET

    ASSET MOVEMENT TEAM 3RD FL, LOCATOR B7-YB17-03-03

    CLEVELAND

    OH OHIO

    44135 US
     PRINCIPAL BANK711 HIGH STREET

    DES MOINES

    IA IOWA

    50392
    QUESTRADE INC./CDS**5650 YONGE ST.,

    Suite 1700

    TORONTO

    ON ONTARIO

    M2M 4G3 CA CANADA
     Raymond James & Associates, Inc.880 CARILLON PKWY

    ST. PETERSBURG

    FL FLORIDA

    33733-2749 US
    RAYMOND JAMES LTD.925 WEST GEORGIA STREET

    SUITE 2200

    VANCOUVER

    BC BRITISH COLUMBIA

    V6C 3L2 CA CANADA
     RBC CAPITAL MARKETS, LLC60 SOUTH 6TH ST.

    MINNEAPOLIS

    MN MINNESOTA

    55402 US
    RBC DOMINION SECURITIES INC21 COMMERCE COURT SOUTH

    2ND FLOOR

    TORONTO

    ON ONTARIO

    M5L 1A7 CANADA
     RELIANCE TRUST COMPANY1100 ABERNATHY RD.

    500 NORTHPARK SUITE 400

    ATLANTA

    GA GEORGIA

    30113 US
    RELIANCE TRUST COMPANY4900 W. BROWN DEER RD

    MILWAUKEE

    WI WISCONSIN

    53223 US
     ROBERT W. BAIRD & CO. INCORPORATED777 E WISCONSIN AVE

    9TH FLOOR

    MILWAUKEE

    WI WISCONSIN

    53202 US
    ROBINHOOD SECURITIES, LLC500 COLONIAL CENTER PARKWAY

    SUITE 100

    LAKE MARY

    FL FLORIDA

    32746 US
     SAFRA SECURITIES LLC546 5TH AVENUE

    NEW YORK

    NY NEW YORK

    10036 US
    SCOTIA CAPITAL (USA) INC.150 KING STREET W

    5TH FLOOR

    TORONTO

    ON ONTARIO

    M5H 1J9 CA CANADA
     SEI PRIVATE TRUST COMPANY1 FREEDOM VALLEY DRIVE

    OAKS

    PA PENNSYLVANIA

    19456 US
    SEI PRIVATE TRUST COMPANY1 FREEDOM VALLEY DRIVE

    OAKS

    PA PENNSYLVANIA

    19456 US
     SG AMERICAS SECURITIES, LLC480 WASHINGTON BLVD.

    20TH FLOOR

    JERSEY CITY

    NJ NEW JERSEY

    07310 US
    SSB - BLACKROCK INSTITUTIONAL TRUST50 California Street

    San Francisco

    CA CALIFORNIA

    94163
     SSB - TRUST CUSTODY30 ADELAIDE ST EAST

    SUITE 800

    TORONTO

    ON ONTARIO

    M5C 3G6 CA CANADA
    SSB&T CO/CLIENT CUSTODY SERVICES1776 HERITAGE DRIVE

    NORTH QUINCY

    MA MASSACHUSETTS

    02171
     STATE STREET BANK & TRUST CO16 WALL STREET

    5TH FLOOR

    NEW YORK

    NY NEW YORK

    10005 US
    STATE STREET BANK & TRUST COMPANY / ISHARES EUROPE1776 HERITAGE DRIVE

    NORTH QUINCY

    MA MASSACHUSETTS

    02171
     STATE STREET BANK & TRUST/STATE STREET TOTALETF1776 Heritage Drive

    NORTH QUINCY

    MA MASSACHUSETTS

    02717
    STATE STREET BANK AND TRUST COMPANY30 ADELAIDE ST EAST

    SUITE 800

    TORONTO

    ON ONTARIO

    M5C 3G6 CA CANADA
     STIFEL, NICOLAUS & COMPANY, INCORPORATED501 N BROADWAY

    ST. LOUIS

    MO MISSOURI

    63102 US
    STONEX FINANCIAL INC.2 PERIMETER PARK SOUTH

    SUITE 100 W

    BIRMINGHAM

    AL ALABAMA

    35243 US
     TD AMERITRADE CLEARING, INC.200 S 108TH AVE

    OMAHA

    NE NEBRASKA

    68154 US
    TD WATERHOUSE CANADA INC

    ATTN: MANDATORY CORPORATE ACTIONS
    77 BLOOR STREET WEST

    3RD FLOOR

    TORONTO

    ON ONTARIO

    M5S 1M2 CA CANADA
     TEXAS TREASURY SAFEKEEPING TRUST COMPANY208 E 10TH ST

    AUSTIN

    TX TEXAS

    78701 US
    THE BANK OF NEW YORK MELLON500 GRANT STREET

    27TH FLOOR

    PITTSBURGH

    PA PENNSYLVANIA

    15258 US
     THE HUNTINGTON NATIONAL BANK7 EASTON OVAL EA4E62

    COLUMBUS

    OH OHIO

    43209 US
    THE NORTHERN TRUST COMPANY333 South Wabash Ave, 32nd Floor

    Attn: Trade Securities Processing

    CHICAGO

    IL ILLINOIS

    60603 US
     TRADESTATION SECURITIES, INC.120 RIVERSIDE PLAZA

    SUITE 1650

    CHICAGO

    IL ILLINOIS

    60606 US
    U.S. BANCORP INVESTMENTS, INC.60 LIVINGSTON AVE

    EP-MN-WN1B

    ST. PAUL

    MN MINNESOTA

    55107-1419 US
     U.S. BANK N.A./ETF1555 N RIVER CENTER DRIVE

    MILWAUKEE

    WI WISCONSIN

    53212
    U.S. BANK NATIONAL ASSOCIATION1555 NORTH RIVERCENTER DRIVE, SUITE 302

    SUITE 302

    MILWAUKEE

    WI WISCONSIN

    53212 US
     UBS AG480 WASHINGTON BLVD.

    12TH FLOOR

    JERSEY CITY

    NJ NEW JERSEY

    07310 US
    UBS FINANCIAL SERVICES INC.1000 HARBOR BOULEVARD

    WEEHAWKEN

    NJ NEW JERSEY

    07086 US
     UBS SECURITIES LLC677 WASHINGTON BLVD

    STAMFORD

    CT CONNECTICUT

    06901 US
    UMB BANK, NATIONAL ASSOCIATION928 GRAND BLVD

    KANSAS CITY

    MO MISSOURI

    64106 US
     VANGUARD MARKETING CORPORATION100 VANGUARD BLVD

    MALVERN

    PA PENNSYLVANIA

    19355 US
    VELOCITY CLEARING, LLC1301 Route 36

    Suite 109 (Attn: Chris Felicetti)

    HAZLET

    NEW JERSEY

    7730 US
     VELOX CLEARING LLC2400 E. KATELLA AVENUE

    SUITE 725A

    ANAHEIM

    CA CALIFORNIA

    92806 US
    VIRTU AMERICAS LLCONE LIBERTY PLAZA, 165 BROADWAY

    5TH FLOOR

    NEW YORK

    NY NEW YORK

    10006 US
     VISION FINANCIAL MARKETS LLC4 HIGH RIDGE PARK

    SUITE 100

    STAMFORD

    CT CONNECTICUT

    06905 US
    WEDBUSH SECURITIES INC1000 WILSHIRE BLVD

    8TH FLOOR

    LOS ANGELES

    CA CALIFORNIA

    90017 US
     WEDBUSH SECURITIES INC.1000 WILSHIRE BLVD.

    LOS ANGELES

    CA CALIFORNIA

    90017 US
    WELLS FARGO BANK, N.A./SIG733 MARQUETTE AVE 4TH FLOOR

    MAC N9306-04D

    MINNEAPOLIS

    MN MINNESOTA

    55402 US
     WELLS FARGO CLEARING SERVICES LLC1 NORTH JEFFERSON

    MAIL CODE: H0006-094

    ST. LOUIS

    MO MISSOURI

    63103 US
    WELLS FARGO SECURITIES, LLC1525 WEST W T HARRIS BLVD

    CHARLOTTE

    NC NORTH CAROLINA

    28262 US
     WILSON-DAVIS & CO., INC.236 SOUTH MAIN STREET

    SALT LAKE CITY

    UT UTAH

    84101 US

    About Scilex Holding Company 

    Scilex Holding Company, a majority-owned by Sorrento Therapeutics, Inc., is an innovative revenue-generating company focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Scilex is uncompromising in its focus to become the global pain management leader committed to social, environmental, economic, and ethical principles to responsibly develop pharmaceutical products to maximize quality of life. Results from the Phase III Pivotal Trial C.L.E.A.R Program for SEMDEXA™, its novel, non-opioid product for the treatment of lumbosacral radicular pain (sciatica), were announced in March 2022.  Scilex has applied for breakthrough therapy designation and expects to seek priority review for SEMDEXA™ for the treatment of sciatica.  Scilex targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with moderate to severe pain.  Scilex launched its first commercial product in October 2018, in-licensed a commercial product in June 2022, and is developing its late-stage pipeline, which includes a pivotal Phase 3 candidate and one Phase 2 and one Phase 1 candidate.  Its commercial product, ZTlido® (lidocaine topical system) 1.8%, or ZTlido®, is a prescription lidocaine topical product approved by the U.S. Food and Drug Administration for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain.  Scilex in-licensed the exclusive right to commercialize Gloperba® (colchicine USP) oral solution, an FDA-approved prophylactic treatment for painful gout flares in adults, in the U.S. Scilex is planning to commercialize Gloperba® in 2023 and is well-positioned to market and distribute the product. Scilex's three product candidates are SP-102 (injectable dexamethasone sodium phosphate viscous gel product containing 10 mg dexamethasone), or SEMDEXA™, a Phase 3, novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, with FDA Fast Track status; SP-103 (lidocaine topical system) 5.4%, a Phase 2, triple-strength formulation of ZTlido®, for the treatment of low back pain, with FDA Fast Track status; and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule, for the treatment of chronic pain, fibromyalgia that has completed multiple Phase 1 trial programs and expected to initiate Phase 2 trials this year. For further information regarding the SP-102 Phase 3 efficacy trial, see NCT identifier NCT03372161 – Corticosteroid Lumbar Epidural Analgesia for Radiculopathy – Full Text View – ClinicalTrials.gov.

    Scilex Holding Company is headquartered in Palo Alto, California, with operations in both Palo Alto and San Diego, California. For further information please visit www.scilexholding.com.

    About Sorrento Therapeutics, Inc.

    Sorrento is a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune disease and COVID-19. Sorrento's multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as Abivertinib, next-generation tyrosine kinase inhibitors ("TKIs"), fully human antibodies ("G-MAB™ library"), immuno-cellular therapies ("DAR-T™"), antibody-drug conjugates ("ADCs"), and oncolytic virus ("Seprehvec™"). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including STI-1558, COVI-MSC™; and diagnostic test solutions, including COVIMARK™.

    Sorrento's commitment to life-enhancing therapies for patients is also demonstrated by our effort to advance a TRPV1 agonist, non-opioid pain management small molecule, resiniferatoxin ("RTX"), and SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXA™), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, and to commercialize ZTlido® (lidocaine topical system) 1.8% for the treatment of postherpetic neuralgia (PHN). RTX has been cleared for a Phase II trial for intractable pain associated with cancer and a Phase II trial in osteoarthritis patients. Positive final results from the Phase III Pivotal Trial C.L.E.A.R. Program for SEMDEXA™, its novel, non-opioid product for the treatment of lumbosacral radicular pain (sciatica), were announced in March 2022. ZTlido® was approved by the FDA on February 28, 2018.

    For more information visit www.sorrentotherapeutics.com.

    Contacts:

    For Scilex Holding Company

    Jaisim Shah

    Chief Executive Officer

    Scilex Holding Company

    960 San Antonio Road

    Palo Alto, CA 94303

    Office: (650) 516-4310

    Email: [email protected]

    Website:  www.sorrentotherapeutics.com and www.scilexholding.com

    Investors and Media Contact:

    Elizabeth Czerepak

    Email: [email protected]

    Website: www.sorrentotherapeutics.com

    Sorrento® and the Sorrento logo are registered trademarks of Sorrento Therapeutics, Inc.

    G-MAB™, DAR-T™, Seprehvec™, SOFUSA™, COVI-MSC™, COVIMARK™, Ovydso™ and Fujovee™ are trademarks of Sorrento Therapeutics, Inc.

    SEMDEXA™ (SP-102) is a trademark owned by Semnur Pharmaceuticals, Inc., a wholly-owned subsidiary of Scilex Holding Company.  A proprietary name review by the FDA is planned.

    ZTlido® is a registered trademark owned by Scilex Pharmaceuticals Inc., a wholly-owned subsidiary of Scilex Holding Company.

    Gloperba® is an exclusive, transferable license to use the trademark by Scilex Holding Company.

    All other trademarks are the property of their respective owners. 

    © 2023 Sorrento Therapeutics, Inc. All Rights Reserved.



    Primary Logo

    Get the next $SCLX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SCLX
    $SRNE

    CompanyDatePrice TargetRatingAnalyst
    Scilex Holding Company
    $SCLX
    1/27/2025$22.00Buy
    D. Boral Capital
    Scilex Holding Company
    $SCLX
    10/16/2024$14.00Buy
    Alliance Global Partners
    Scilex Holding Company
    $SCLX
    6/13/2024$13.00Buy
    Rodman & Renshaw
    Scilex Holding Company
    $SCLX
    10/16/2023$4.00Buy
    B. Riley Securities
    Scilex Holding Company
    $SCLX
    10/13/2023$4.00Buy
    B. Riley Securities
    Scilex Holding Company
    $SCLX
    10/9/2023$12.00Buy
    H.C. Wainwright
    Sorrento Therapeutics Inc.
    $SRNE
    11/2/2022$5.00Overweight
    Cantor Fitzgerald
    Sorrento Therapeutics Inc.
    $SRNE
    8/9/2021$30.00 → $26.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $SCLX
    $SRNE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Scilex Holding Company to Present Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FL.

      PALO ALTO, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company")), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced an upcoming presentation of post-hoc analysis of the C.L.E.A.R. trial (Corticosteroid Lumbar Epidural Analgesia in Radiculopathy) interpreting clinical meaningfulness of safety and efficacy of SP-102 (SEMDEXA™) for the treatment of lumbosacral radicular pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicia

      5/1/25 9:00:00 AM ET
      $SCLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Scilex Holding Company Regains Compliance with NASDAQ Minimum Bid Price Rule

      PALO ALTO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company")), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that it has received notification from The Nasdaq Stock Market LLC that the Company has regained compliance with the minimum closing bid price requirement under Nasdaq Listing Rule 5550(a)(2). To regain compliance, the Company was required to maintain a minimum closing bid price of $1.00 per share for at least ten consecutive trading days.

      4/30/25 1:46:47 PM ET
      $SCLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from April 11, 2025 to May 2, 2025

      PALO ALTO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company")), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that its Board of Directors has approved changing the previously announced record date of April 11, 2025 for its previously announced dividend of Scilex preferred stock (the "Dividend") to its stockholders and certain other securityholders of Scilex. The new record date for the Dividend will be May 2, 2025 (the "New Record Date"). Subject

      4/22/25 9:00:00 AM ET
      $SCLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SCLX
    $SRNE
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Scilex Holding Company

      SCHEDULE 13G/A - Scilex Holding Co (0001820190) (Subject)

      5/8/25 4:15:17 PM ET
      $SCLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form POS AM filed by Scilex Holding Company

      POS AM - Scilex Holding Co (0001820190) (Filer)

      5/7/25 5:30:11 PM ET
      $SCLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form POS AM filed by Scilex Holding Company

      POS AM - Scilex Holding Co (0001820190) (Filer)

      5/7/25 5:24:45 PM ET
      $SCLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SCLX
    $SRNE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Officer Shah Jaisim bought $13,800 worth of shares (30,000 units at $0.46), increasing direct ownership by 27% to 139,333 units (SEC Form 4)

      4 - Scilex Holding Co (0001820190) (Issuer)

      12/18/24 7:04:41 PM ET
      $SCLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Executive Chairperson Ji Henry bought $8,351 worth of shares (8,888 units at $0.94), increasing direct ownership by 3% to 320,161 units (SEC Form 4)

      4 - Scilex Holding Co (0001820190) (Issuer)

      10/31/24 12:44:57 PM ET
      $SCLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Officer Shah Jaisim bought $31,670 worth of shares (32,000 units at $0.99), increasing direct ownership by 41% to 109,333 units (SEC Form 4)

      4 - Scilex Holding Co (0001820190) (Issuer)

      10/29/24 6:59:31 PM ET
      $SCLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SCLX
    $SRNE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $SCLX
    $SRNE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $SCLX
    $SRNE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • D. Boral Capital initiated coverage on Scilex Holding with a new price target

      D. Boral Capital initiated coverage of Scilex Holding with a rating of Buy and set a new price target of $22.00

      1/27/25 8:08:33 AM ET
      $SCLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alliance Global Partners initiated coverage on Scilex Holding with a new price target

      Alliance Global Partners initiated coverage of Scilex Holding with a rating of Buy and set a new price target of $14.00

      10/16/24 8:01:57 AM ET
      $SCLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Rodman & Renshaw initiated coverage on Scilex Holding with a new price target

      Rodman & Renshaw initiated coverage of Scilex Holding with a rating of Buy and set a new price target of $13.00

      6/13/24 7:16:15 AM ET
      $SCLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Scilex Holding Company (Amendment)

      SC 13D/A - Scilex Holding Co (0001820190) (Subject)

      4/25/24 5:25:28 PM ET
      $SCLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Scilex Holding Company (Amendment)

      SC 13D/A - Scilex Holding Co (0001820190) (Subject)

      3/5/24 4:22:28 PM ET
      $SCLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Sorrento Therapeutics Inc. (Amendment)

      SC 13G/A - Sorrento Therapeutics, Inc. (0000850261) (Subject)

      3/10/23 11:21:36 AM ET
      $SRNE
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Large owner Sclx Stock Acquisition Jv Llc disposed of 3,250,000 shares, decreasing direct ownership by 6% to 51,039,214 units (SEC Form 4)

      4 - Scilex Holding Co (0001820190) (Issuer)

      1/23/25 7:49:49 PM ET
      $SCLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Sclx Stock Acquisition Jv Llc disposed of 779,371 shares, decreasing direct ownership by 1% to 54,289,214 units (SEC Form 4)

      4 - Scilex Holding Co (0001820190) (Issuer)

      1/17/25 8:27:54 PM ET
      $SCLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Sclx Stock Acquisition Jv Llc disposed of 5,000,000 shares, decreasing direct ownership by 8% to 55,068,585 units (SEC Form 4)

      4 - Scilex Holding Co (0001820190) (Issuer)

      1/6/25 7:12:44 PM ET
      $SCLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SCLX
    $SRNE
    Financials

    Live finance-specific insights

    See more
    • Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from April 11, 2025 to May 2, 2025

      PALO ALTO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company")), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that its Board of Directors has approved changing the previously announced record date of April 11, 2025 for its previously announced dividend of Scilex preferred stock (the "Dividend") to its stockholders and certain other securityholders of Scilex. The new record date for the Dividend will be May 2, 2025 (the "New Record Date"). Subject

      4/22/25 9:00:00 AM ET
      $SCLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from January 28, 2025 to April 11, 2025

      PALO ALTO, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company")), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and, following the formation of its proposed joint venture with IPMC Company, neurodegenerative and cardiometabolic disease, today announced that its Board of Directors has approved changing the previously announced record date of January 28, 2025 for its previously announced dividend of Scilex preferred stock (the "Dividend") to its stockholders and certain other securityholders of Scilex. The new record

      3/10/25 9:00:00 AM ET
      $SCLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to April 14, 2025

      US Bankruptcy Court for the Southern District of Texas issued an order to extend the lock-up period on the Scilex Dividend Stock, previously distributed by Sorrento, to April 14, 2025.Accordingly, any shares of the Dividend Stock (including any such shares held by brokerage firms) may not be sold, transferred or otherwise disposed of.Scilex's transfer agent, Continental Stock Transfer & Trust Company, has been notified of the lock-up extension to April 14, 2025. PALO ALTO, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company")), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain manag

      1/31/25 9:00:00 AM ET
      $SCLX
      $SRNE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Commercial Physical & Biological Resarch

    $SCLX
    $SRNE
    Leadership Updates

    Live Leadership Updates

    See more
    • Scilex Holding Company Strengthens Board of Directors with Appointment of Highly Accomplished Leader in Interventional and Multidisciplinary Spine, Musculoskeletal and Orthopedic Care, Annu Navani, M.D.

      PALO ALTO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex" or the "Company"))), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that it has added to its Board of Directors a highly accomplished leader in interventional and multidisciplinary spine, musculoskeletal and orthopedic care, Annu Navani, M.D. Dr. Navani has served as the Chief Executive Officer of Comprehensive Spine and Sports Center since 2008, a leader in interventional and multidisciplinary spine, musculoskeletal, and orthopedic care. Over th

      7/23/24 9:00:00 AM ET
      $SCLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Scilex Holding Company Launches New Website to Showcase Growing Portfolio of Non-Opioid Products and Pipeline Information Updates

      PALO ALTO, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company"))), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced the launch of its redesigned website showcasing the Company's growing portfolio of non-opioid pain management therapeutics. The new website can be accessed by visiting www.scilexholding.com, The features of the new and improved website include: Sleek, modern web design with dynamic elements and illustrations;An overview of the Company's science and expanded product portfolio and pr

      3/4/24 9:00:00 AM ET
      $SCLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Scilex Holding Company, a Sorrento Company, announces that the Honorable Tommy G. Thompson has joined the Scilex Board of Directors

      PALO ALTO, Calif., July 05, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex"), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))), a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients with acute and chronic pain, announced today the appointment of the Honorable Tommy G. Thompson, former Secretary of the United States Department of Health and Human Services ("HHS") and former Governor of Wisconsin, to its Board of Directors. Governor Thompson's appointment is effective immediately. Governor Thompson currently serves as the Chief Executive Officer of Thomp

      7/5/22 2:04:42 PM ET
      $SRNE
      $VCKA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)